Awards for “TEVA PHARMACEUTICALS USA, INC.”
25 awards on this page · sorted by amount · page 5
| Award ID | Recipient | Awarding agency | Amount | Start | End | NAICS | Description |
|---|---|---|---|---|---|---|---|
| SPE2DP24F3173 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $635.22K | 2024-03-13 | 2024-03-26 | 325412 | 8510500531!ADENOVIRUS TYPE 4 A |
| SPE2DP24F2823 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $635.22K | 2024-02-22 | 2024-02-27 | 325412 | 8510462257!ADENOVIRUS TYPE 4 A |
| SPE2DP24F1992 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $635.22K | 2024-01-25 | 2024-01-30 | 325412 | 8510401546!ADENOVIRUS TYPE 4 A |
| V761C70024 | TEVA PHARMACEUTICALS USA, INC. | Department of Veterans Affairs | $629.71K | 2007-04-17 | 2007-10-22 | 325412 | DRUGS AND BIOLOGICALS FOR CMOP 1ST AND 2ND QTR FY 2007 |
| SPE2DP23F6116 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $610.79K | 2023-09-11 | 2023-09-19 | 325412 | 8510134905!ADENOVIRUS TYPE 4 A |
| SPE2DP23F6109 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $610.79K | 2023-09-12 | 2023-09-19 | 325412 | 8510134412!ADENOVIRUS TYPE 4 A |
| SPE2DP23F5674 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $610.79K | 2023-08-22 | 2023-08-29 | 325412 | 8510093097!ADENOVIRUS TYPE 4 A |
| SPE2DP23F5668 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $610.79K | 2023-08-22 | 2023-08-29 | 325412 | 8510092919!ADENOVIRUS TYPE 4 A |
| SPE2DP23F5010 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $610.79K | 2023-07-18 | 2023-07-25 | 325412 | 8510016878!ADENOVIRUS TYPE 4 A |
| SPE2DP23F5009 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $610.79K | 2023-07-17 | 2023-07-25 | 325412 | 8510016874!ADENOVIRUS TYPE 4 A |
| SPE2DP23F5008 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $610.79K | 2023-07-18 | 2023-07-25 | 325412 | 8510016829!ADENOVIRUS TYPE 4 A |
| SPE2DP23F5004 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $610.79K | 2023-07-18 | 2023-07-25 | 325412 | 8510016424!ADENOVIRUS TYPE 4 A |
| SPE2DP23F4570 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $610.79K | 2023-06-20 | 2023-06-27 | 325412 | 8509963793!ADENOVIRUS TYPE 4 A |
| SPE2DP23F4569 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $610.79K | 2023-06-20 | 2023-06-27 | 325412 | 8509963792!ADENOVIRUS TYPE 4 A |
| SPE2DP23F4568 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $610.79K | 2023-06-20 | 2023-06-27 | 325412 | 8509963790!ADENOVIRUS TYPE 4 A |
| SPE2DP23F4566 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $610.79K | 2023-06-20 | 2023-06-27 | 325412 | 8509963745!ADENOVIRUS TYPE 4 A |
| SPE2DP23F4564 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $610.79K | 2023-06-20 | 2023-06-27 | 325412 | 8509963741!ADENOVIRUS TYPE 4 A |
| SPE2DP23F4563 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $610.79K | 2023-06-20 | 2023-06-27 | 325412 | 8509963705!ADENOVIRUS TYPE 4 A |
| SPE2DP23F3375 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $610.79K | 2023-04-19 | 2023-04-25 | 325412 | 8509839610!ADENOVIRUS TYPE 4 A |
| SPE2DP23F2300 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $610.79K | 2023-02-22 | 2023-02-28 | 325412 | 8509714909!ADENOVIRUS TYPE 4 A |
| SPE2DP23F2299 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $610.79K | 2023-02-22 | 2023-02-28 | 325412 | 8509714905!ADENOVIRUS TYPE 4 A |
| SPE2DP23F2295 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $610.79K | 2023-02-22 | 2023-02-28 | 325412 | 8509714861!ADENOVIRUS TYPE 4 A |
| SPE2DP23F0889 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $587.3K | 2022-12-06 | 2022-12-20 | 325412 | 8509568680!ADENOVIRUS TYPE 4 A |
| SPE2DP22F7352 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $587.3K | 2022-09-13 | 2022-09-20 | 325412 | 8509383416!ADENOVIRUS TYPE 4 A |
| SPE2DP22F7350 | TEVA PHARMACEUTICALS USA, INC. | Department of Defense | $587.3K | 2022-09-13 | 2022-09-20 | 325412 | 8509383413!ADENOVIRUS TYPE 4 A |